this piece corresponds to the legacy myPDB login in the form of a bootstrap modal, will likely retire-->

LUR

{2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl}acetic acid

LUR is found in 6 entries

LUR as free ligands, exist in 6 entries. Example includes: 4RRW 4IIZ 4OTY

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo



Chemical Component Summary

Name{2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl}acetic acid
Identifiers2-[2-[(2-chloranyl-6-fluoranyl-phenyl)amino]-5-methyl-phenyl]ethanoic acid
FormulaC15 H13 Cl F N O2
Molecular Weight293.72 g/mol
TypeNON-POLYMER
Isomeric SMILESCc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1
InChIInChI=1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20)
InChIKeyKHPKQFYUPIUARC-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count33
Chiral Atom Count0
Chiral Atomsn/a
Bond Count34
Aromatic Bond Count12
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB01283 Different stereochemistry
NameLumiracoxib
Groups
  • approved
  • investigational
DescriptionLumiracoxib is a COX-2 selective inhibitor non-steroidal anti-inflammatory drug. On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have also followed suit in recalling the drug.
Synonyms
  • 2-((2-chloro-6-Fluorophenyl)amino)-5-methylbenzeneacetic acid
  • COX 189
  • COX-189
  • COX189
  • Lumiracoxibum
Brand NamesPrexige
Affected OrganismHumans and other mammals
IndicationFor the acute and chronic treatment of the signs and symptoms of osteoarthritis of the knee in adults.
PharmacologyLumiracoxib has a different structure from the standard COX-2 inhibitors (e.g. celecoxib). It more closely resembles the structure of diclofenac (one chlorine substituted by fluorine, the phenylacetic acid has another methyl group in meta position), making it a member of the arylalkanoic acid family of NSAIDs. It binds to a different site on the COX-2 receptor than the standard COX-2 inhibitors. It displays extremely high COX-2 selectivity.
Mechanism of actionThe mechanism of action of lumiracoxib is due to inhibition of prostaglandin synthesis via inhibition of cyclooygenase-2 (COX-2). Lumiracoxib does not inhibit COX-1 at therapeutic concentrations.
Categories
  • Acids, Carbocyclic
  • Analgesics
  • Analgesics, Non-Narcotic
  • Anti-Inflammatory Agents
  • Anti-Inflammatory Agents, Non-Steroidal
ATC-CodeM01AH06
AHFS-Code28:08.04.08
CAS number220991-20-8
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682